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Abstract
An efficient and scalable synthesis of new oligonucleotide monomers was developed for replacement 
of the phosphodiester backbone of RNA by a sulfonamide containing backbone to enable construction 
of sulfonamide antisense oligonucleotides (SaASOs). It was shown that by employing these 
sulfonamide RNA(SaRNA) monomers it was possible to synthesize oligomers in solution. The 
properties of a sulfonamide moiety replacement were evaluated by incorporation of a SaRNA-
monomer into a DNA strand and performing thermal stability tests of the resulting DNA and RNA-
double-strand hybrids. Although the sulfonamide modification caused a decrease in melting 
temperature (Tm) of both hybrids, it was lower for the sulfonamide containing DNA-RNA hybrid than 
that for the sulfonamide containing DNA-DNA hybrid.
Introduction
The development of oligonucleotide synthetic methods has led to a plethora of chemical approaches 
for preparation of derivatives and analogues. As a result, a range of chemically modified antisense 
oligonucleotides (ASOs) is now available. Over the years further improvements of the synthesis of the 
nucleotide building blocks and overall efficiency of oligonucleotide syntheses made it possible that 
sufficient quantities of ASOs became available for clinical use. This has culminated in recent FDA-
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approvals of three ASOs for treatment of homozygous familial hypercholesterolemia (Kynamro®),1 
Duchenne muscular dystrophy (Eteplirsen®),2 and spinal muscular atrophy (Spinraza®).2 The 
developments in siRNA and more recently in CRISPR research have sparked a renewed interest into 
innovative oligonucleotide chemistries.
Excellent reviews have discussed the different important aspects of ASOs.2-7 Understandably, because 
nucleic acids have a sugar phosphate backbone, the majority of ASOs are phosphate analogues. 
Especially prominent are the thiophosphate containing ASOs (including Fomivirsen and Spinraza). 
Nevertheless, thiophosphate ASO chemistry remains challenging and the introduction of additional 
phosphor chiral centres leads to a complex mixture of ASOs. However, the development of ASOs 
completely devoid of a sugar phosphate backbone, peptide nucleic acids (PNAs), in the early nineties, 
showed that it is possible to design other readily accessible mimics of nucleic acids, with improved 
properties compared to the existing ASOs.8 It is therefore somewhat surprising that relatively little 
attention has been spent on sulfur-based backbone modifications in comparison to phosphorus 
modifications as these also give rise to tetrahedral geometries. The oxygen atoms attached to a 
tetrahedral sulfur atom are not charged, so the resulting sulfur-containing linkage will likely 
contribute to easier penetration into cells as opposed to the negative charge of an oxygen or sulfur 
atom attached to a tetrahedral phosphorous atom. Furthermore, chemically and metabolically stable 
bonds to the tetrahedral sulfur atom can be introduced. Lastly, the absence of chirality in the linkers 
connecting the nucleotide building blocks results in the formation of a single stereoisomer in contrast 
to the phosphorus-containing linkages, which are present in the therapeutically used ASOs.
The lack of sulfur-containing ASOs (S-ASO) could be due to difficulties in developing a highly 
efficient oligomerisation chemistry strategy. The realization of efficient syntheses of phosphorus 
oligonucleotides took several decades and included the breakthrough transition from phosphor 
chemistry pioneered by Khorana et al.9 to phosphoramidite chemistry especially advanced by 
Caruthers et al.10,11 These impressive developments also set the stage for ASOs with a 
phosphor(di)amidate or phosphorthioate backbone which are present in the FDA approved ASOs. The 
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chemistry development of these ASOs and subsequent clinical studies took several years. This at least 
partly explains the low interest in the development of novel S-ASOs.8 
Other reasons for the absence of S-ASOs might be the potential properties of several of these 
derivatives. Bivalent sulfur containing ASOs 112 are likely to be practically insoluble in aqueous 
solvents. This is likely also the case for sulfone containing ASOs 312-14. Sulfoxide containing ASOs 2 
are probably more polar and therefore better soluble in aqueous solvents, but the sulfoxide moiety is 
chiral leading to diastereomeric mixtures of ASOs and for this reason may not have been investigated. 
Sulfonate (4 and 515) or sulfate containing ASOs 6 are of course inherently unstable and therefore 
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Figure 1. Sulfur containing ASOs. ASO 1, ASO 3, ASO 7 and ASOs 8 have been described in the 
literature; ASOs 4 - 6 are expected to be unstable; ASO 9 is described in this work.
However, sulfur containing ASOs containing the sulfonamide moiety (8 and 9) may be attractive, 
since the sulfonamide moiety is more polar than the sulfone moiety in ASO 3 and the presence of an 
amide bond hints at a synthetic possibility of repetitive formation so that an ASO containing several 
sulfonamide moieties should be synthetically accessible. In view of its anticipated polarity the 
sulfamide moiety in ASO 716 also seemed an interesting alternative.
Two types of sulfonamide containing ASOs (SaASOs) are possible. (Figure 1) In the first type (8) the 
sulfonamide moiety is obtained by coupling of a 3'-amino nucleoside derivatives with a 5'-sulfonyl 
chloride nucleoside derivative. The introduction of this moiety was first described by Widlanski et 
al.17 We have improved the synthetic strategy by development of more convenient nucleoside building 
blocks in which the amine group was masked as an azide allowing in principle a repetitive cycle of 
two reactions - (1) unmasking of the azide and (2) coupling of resulting amine and sulfonyl chloride - 
which can be used for the construction of sulfonamide containing ASOs.18 Nevertheless, this approach 
had the disadvantage that a relatively hindered 3’-amino functionality has to act as the nucleophile to 
form the sulfonamide moiety. The original method of Khorana for synthesis of a phosphate triester 
suffered from a similar disadvantage in that a secondary 3'-hydroxy functionality had to attack the 
activated phospho triester derivative (Figure 2). This was later remedied by the development of the 
phosphoramidite method. Not only is a phosphoramidite derivative much more reactive than any 
activated phospho triester derivative, but also in the amidite method the 5' -primary- hydroxy 
functionality is used as a better, less hindered, nucleophile (Figure 2).
Thus, we wished to develop an efficient and scalable synthesis for sulfonamide containing ASOs 
obtained by reaction of a 5'-amino group containing nucleotide derivative with a suitably activated 3'-
sulfonic acid derivative (Figure 2).
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Figure 2. Proposed sulfonamide ASO (SaASO) construction by reaction of a 5'-amino nucleophile 
with a 3'-sulfur electrophile comparable to the phosphoramidite method of Caruthers and co-
workers.9,10
Results and discussion
Preparation of the SaRNA nucleoside synthon
When considering molecular construction of biopolymer mimetics such as sulfonamide containing 
ASOs, the most important issues are (1) convenient access to their building blocks and (2) 
requirement of a versatile and efficient coupling strategy for formation of a sulfonamide linkage. 
Therefore, we wished to achieve versatile access to the building blocks for sulfonamide ribose based 
oligonucleotides (SaRNA) to realize both aims. It would be beneficial that the devised molecular 
construction strategy is in principle amenable for translation to a solid phase synthesis protocol. 
Page 5 of 42
ACS Paragon Plus Environment






























































Finally, convenient adaptation of the synthesis to achieve molecular construction of RNA/DNA – 
SaRNA hybrids was desired. With these requirements, we set out to devise a synthetic strategy.
In our opinion the crucial issue in the molecular construction of SaRNA was the availability of a 
versatile method for synthesis of the sugar sulfonamide backbone (Figure 1). In order to ultimately 
couple the nucleotide SaRNA building blocks in a repetitive manner, one needs a readily 
deprotectable amine as well as a readily activatable sulfonic acid moiety (Figure 2). The azide, 
serving as a 'masked' amine and a hindered sulfonate ester have been used earlier by us in the 
preparation of a sulfonamide linkage.18 In this strategy the 5'-azide is unmasked at every synthesis 
cycle and the resulting 5'-amine is then coupled to 3'-activated sulfonic acid derivative, followed by 




















































Scheme 1. Required building blocks and the repetitive unmasking and coupling steps for assembly of 
the sulfonamide backbone
Thus, an easily scalable preparation of the nucleoside synthons was required, which could be 
converted into activated building blocks in an easy and efficient manner. In the past we have used 
diacetone-D-glucose for preparation of the SaRNA nucleoside synthons.18 However, it was found that 
introduction of the required azide onto the 5'-position later in the synthetic route was accompanied by 
side reactions of the sulfonate group and therefore less efficient (Scheme 2).
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Scheme 2. Side reaction of azide with the sulfonate ester
To remedy this a very efficient 5-step synthesis was developed starting from the 5-Tosyl acetone-D-
xylose 10 which was easily prepared from readily available D-xylose, (Scheme 3).19 In a simple 
procedure azide 11 was obtained in quantitative yield via a nucleophilic displacement reaction of 
tosylate 10.20 Next, the secondary alcohol functionality of compound 11 was oxidised to ketone 12 in 
a highly efficient TEMPO radical oxidation.21 Without further purification the sulfonate ester moiety 
was introduced via a Horner-Wadsworth-Emmons reaction with phosphonate 1322 to give vinyl 
sulfonate 14 as a mixture of E/Z alkenes which was used without purification.23 Sodium borohydride 
reduction of the crude 14 in a Michael reaction was stereoselective because of the steric effect of the 
acetal moiety and yielded a single isomer of compound 15 in 48% overall yield over 3 steps.24 The 
crucial di-acetate synthon 16 to be used for incorporation each of the nucleobases, was obtained in a 
acetal deprotection/ acetylation step in 66% yield.25
Scheme 3. SaRNA nucleoside synthon synthesis
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Synthesis of activated SaRNA nucleotide building blocks
Nucleobases were introduced using standard literature procedures and the protected SaRNA 
nucleotide building blocks 17a,b,e,d were obtained in acceptable to good yields (44% - 74%, Scheme 
4).26 The nucleobase protecting groups were similar to those used for the synthesis of oligonucleotides 
analogues with a peptide backbone.6 Although slight variations in the introduction of the nucleobases 
is possible, the indicated conditions gave the best yields and reproducible results. For example, it was 




































































MeCN, 0 oC, 3h
Bz-Cytosine,
HMDS, (NH4)2SO4,
TMSOTf, DCE, reflux, 3h
17a, 72%
17e, 36% 17d, 74%
Scheme 4. Synthesis of the S-RNA nucleotide building blocks (BSA: bis-trimethylsilylacetamide, 
DPC: N,N-Diphenyl Carbamate)
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The sulfonamide linkage was introduced using a sulfonamide pentafluorophenyl (PFP) ester instead 
of the obvious and reactive sulfonyl chloride, since the former is more stable and sufficiently reactive 
to give rise to formation of sulfonamide linkage in good yields.27,28 To realize the preparation of 
SaRNA nucleotide PFP esters 20a-d, sulfonate esters 17a-d were converted into sulfonate 
tetrabutylammonium salts 18a-d by heating with TBAI.29 Using tetrabutylammonium sulfonate salts 
instead of sodium salts afforded compounds that had better solubility properties in organic solvents. 
This proved to be crucial for the synthesis of sulfonyl chlorides and subsequent PFP esters as the 
reactions were cleaner and gave rise to higher yields. Also, it was possible to conveniently purify the 
TBA salts 18a-d by normal phase flash chromatography. Next, sulfonyl chlorides 19a-d were 
obtained using POCl3 in a very clean reaction not requiring any purification for the preparation of the 
PFP-esters. Other reagents such as SOCl2 in the presence or absence of a catalytic amount of DMF18 
resulted in side reactions with protecting groups on nucleobases that is 19a, 19c and 19d.  In a simple 
nucleophilic substitution reaction required active PFP-esters 20a-d were obtained in good to excellent 
yields, excepting 20c. For synthesis of the latter G-PFP building block 20c, the DPC-group had to be 
removed first due to side reactions further through the synthesis (Scheme 5).
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Scheme 5. Synthesis of active (PFP) esters of SaRNA nucleotide building blocks
These nucleotide PFP-esters are the central building blocks to be used for the molecular construction 
both in solution and in future on solid phase of sulfonamide anti-sense oligonucleotides.
Synthesis in solution of SaRNA
As a first illustration of the use of these PFP-active ester nucleotide building blocks for the synthesis 
of SaRNA in solution tetranucleotide AUAU (26) was selected (Scheme 6). For this the 3'-end 
nucleotide was obtained by conversion of U-nucleotide building block 20b to the sulfonamide 21, of 
which the azide moiety was unmasked by hydrogenation to give amine 22.30 Amine 22 was then 
coupled to adenine PFP-building block 20a to give A-U dimer 23. Dimer 23 was subsequently 
unmasked as above and immediately coupled to uracil PFP-ester building block 20b. Since this 
reaction was slower, coupling was carried out under microwave conditions and tetrabutyl ammonium 
chloride (TBAC) was added as a nucleophilic catalyst for activation by supposedly in situ formation 
of the sulfonyl chloride as has been described in the literature27 to give 24. Repetition of the 
unmasking and coupling cycle using adenine PFP-building block 20a again gave the final crude 
tetranucleotide 25. After deprotection overnight using a 7M ammonia in methanol solution, the crude 
SaRNA tetranucleotide 26 was obtained which was purified using preparative HPLC. The resulting 
SaRNA-tetranucleotide was stable and no decomposition was observed after six months storage at 
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Scheme 6. Synthesis in solution of SaRNA-tetranucleotide AUAU
To evaluate the removal of the nucleobase-protecting groups in monomers 20c and 20d, a GC SaRNA 
dinucleotide 30 was synthesized in a similar manner as tetranucleotide 26 with efficient removal of 
the protecting group in an overall yield of 12%, Scheme 7.
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Scheme 7. Synthesis of SaRNA dinucleotide CG
Solid phase synthesis of a DNA-SaRNA hybrid for melting experiments
To assess whether the sulfonamide moiety was indeed a good mimic of the phosphodiester linkage, a 
single sulfonamide moiety was incorporated into a DNA strand and study the melting behaviour of 
resulting DNA-SaRNA and compare it to the melting of the corresponding unmodified double-
stranded(ds) DNA and ds RNA-DNA. For molecular construction of the required DNA-SaRNA 
hybrid 46 a sulfonamide containing dinucleotide (45) was needed and synthesized (Scheme 8). The 
resulting dinucleotide had to contain a dimethoxy trityl (DMT) group at the 5' end and a 
phosphoramidite moiety at the 3' end, so that it would be compatible with standard solid phase 
synthesis of DNA by the phosphoramidite method. Starting from diacetone-D-glucose (31) the 
sulfonate ester moiety was introduced similarly to the preparation of 15 (Scheme 3). In this synthesis 
di-acetal 34 was converted into diol-acetal 35, so that one carbon atom could be removed by 
oxidation,18 leading ultimately to 5'-levulinic acid protected sulfonate ribose derivative 38. This 
derivative was suitable for introduction thymine thus affording 39. Hydrolysis of the iso-butyl 
sulfonate ester moiety in 39 could be achieved in the presence of the levulinic ester moiety, after 
which a 5’-amino 3’-TBDMS protected deoxy-thymidine derivative31 was reacted with PFP-ester 40 
and gave sulfonamide containing dinucleotide derivative 41. In the final steps the DMT-protective 
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group was introduced at the 5'-end and the phosphoramidite moiety at the 3'-end, thereby completing 
the synthesis of sulfonamide containing dinucleotide 45. This dinucleotide building block was used on 
a ABI 394 DNA-synthesizer. Thus, the dinucleotide was incorporated in the sequence described by 
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Scheme 8. Synthesis of a phosphoramidite SaRNA- TT-dinucleotide 45 compatible with standard 
solid phase DNA-synthesis.
Melting temperatures (Tm) were determined of the parent DNA-DNA* and DNA-RNA hybrids as 
well as of the 46-DNA and 46-RNA hybrids (Figure 3). The incorporation of a sulfonamide linkage 
led to a decrease in melting temperature, although this decrease was lower, going from a DNA-RNA 
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hybrid to a 46-RNA hybrid (Δ T = -4.4°), as compared to going from a DNA-DNA* hybrid to a 46-
RNA hybrid (Δ T = -9.4°). This is important considering possible applications as antisense agents 
mainly targeting RNA. These results are in agreements with earlier results of Widlanski et al.13 
obtained upon incorporation of sulfonamides of the different geometry with a deoxyribose sugar 
(Figure 1, SaASO 8).
Figure 3. Melting curves of ds SaRNA containing hybrids as compared to those of native ds DNA 
and ds RNA-DNA
Conclusion
We have developed a versatile synthesis of the complete set of SaRNA nucleotide building blocks 
with distinct possibilities to expand the synthesis to sulfonamide DNA nucleotide building blocks and 
other scaffold modifications. Although nucleotide coupling using their PFP esters in solution is 
optimal, there is room for improvement in light of further development of the solid phase synthesis of 
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dinucleotide building block, which could be used in a standard phosphoramidite solid phase synthesis 
protocol leading to a DNA-SaRNA hybrid still capable of formation of double-stranded molecules 
both with DNA and RNA. Although we have the distinct impression that the presented approach for 
molecular construction of sulfonamide antisense oligonucleotides involving a primary 5'-amine is 
ultimately better than the approach using the more hindered 3'- amine described in the past by us18 and 
others,17 this still has to be rigorously proven in future research by (solid phase) synthesis of 
sulfonamide antisense oligonucleotides and/or sulfonamide/phosphodiester chimera of considerable 
size. Nevertheless, the convenient synthesis of the SaRNA nucleotide building blocks as well as the 
synthesis of a chimera has demonstrated that molecular construction of sulfonamide ASOs is an 
achievable goal, with likely applications in ensuing areas, where ASOs are used as therapeutics.
Experimental section
General information
All analytical or HPLC grade chemicals and solvents were purchased from commercial sources and 
were used as received unless stated otherwise. DNA and RNA sequences were purchased from 
Eurogentec. Microwave reactions were performed using a CEM Discover® Sp reactor in a sealed 
glass container with an external IR temperature sensor and magnetic frequency of 2455MHz. Heating 
of reactions was performed using aluminium heating blocks. 1H NMR, 13C NMR and 19F spectra were 
recorded on a Bruker AVIII 400 MHz Spectrospin spectrometer in CDCl3. Chemical shifts (δ) are 
reported in parts per million (ppm) relative to trimethylsilane (TMS, 0.00 ppm), CDCl3 (7.26 ppm) or 
CFCl3(0.00 ppm). TLC was carried out on silica gel plates (Merck 60F254) and visualization was 
carried out by both UV detection (254 nm) and staining (anisaldehyde, bromocresol green) followed 
by heating.  For column chromatography, a Biotage®-Isolera™ was used together with Biotage Kp-
Sil silica cartridges. Dry solvents (THF, DCM) were dispensed from Pure Solv™ 500 Solvent 
Purification System and other dry solvents (acetonitrile, DMF) were obtained from freshly opened 
commercially available HPLC grade solvents by removal of residual water with activated 4 Å 
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molecular sieves overnight. HRMS-ESI was recorded on Bruker microTOFq High Resolution Mass 
Spectrometer in the positive or negative mode.  Petroleum ether used refers to a mixture with boiling 
point of 40-60 °C. Liquid chromatography mass spectrometry (LCMS) was carried out on a Thermo 
Scientific LCQ Fleet quadrupole mass spectrometer with a Dionex Ultimate 3000 LC using a Dr 
Maisch Reprosil Gold 120 C18 column (110 Å, 3 μm, 150 Å~4.0 mm), using a 0-100% linear 
gradient of buffer A(95% H2O, 5% MeCN, 0.1% TFA) into buffer B(95% MeCN, 5% H2O, 0.1% 
TFA) in 10 or 40 minutes. Deionised water was obtained on a Milli-Q® station (Merck Millipore). 
Preparative HPLC was carried out using Angilent Technologies 1260 Infinity Preparative-scale 
Purification system. Separation was achieved on a Phenomenex Gemini®, 10 μm C18 110 ̊A AXIA, 
250 x 21.2 mm. A linear gradient of 0 → 50% buffer A into buffer B. All runs were conducted over 
80 minutes with a flow rate of 12.5 mL/Min. Fraction collection was based on UV absorption detected 
at both 214 and 254 nm. Analytical HPLC was carried out with a Shimadzu instrument consisting of a 
communication module (CBM-20A), auto-sampler (SIL-20HT), pump modules(LC-20AT), UV/Vis 
detector(SPD-20A) and system controller (LabsolutionsV5.54SP), with a Phenomenex Gemini®, 5 
μm C18 110 ̊A AXIA, 250 x4.60 mm. UV measurements were recorded at 214 and 254 nm, by use of 
a standard protocol using a 0-100% linear gradient of buffer A into buffer B in 40 minutes.
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methylbenzenesulfonate 10: To a stirring solution of D-Xylose (50.0 g, 330 mmol) in acetone (1 L) 
was added dry CuSO4 (66 g) and conc. H2SO4 (5mL).  The resulting suspension was stirred at room 
temperature overnight, after which the reaction mixture was filtered and quenched with conc. NH4OH 
(16mL).  The newly formed precipitate was filtered off and the supernatant was concentrated in vacuo 
to give a thick syrup, which was dissolved in MeOH : H2O (4:1, 500 mL) after which 1 M HCl (10 
mL) was added.  The resulting mixture was stirred for 3 h at room temperature. The volume of the 
mixture was reduced in vacuo and co-evaporated with EtOH and toluene to give a thick syrup.  This 
syrup was dissolved in DCM (300 mL) dried over MgSO4 and concentrated in vacuo to give crude 
protected D-xylose derivative (Bozo et al.19).  After dissolving the D-Xylose derivative in DCM 
(900 mL), TEA (93 mL, 670 mmol) was added and the mixture was cooled to 0°C. To the stirring 
mixture at 0°C was added dropwise a solution of TosCl (69.0 g, 370 mmol) in DCM. The reaction 
mixture was then warmed to room temperature and stirred overnight. 1 M HCl was added to the 
reaction mixture and the resulting solution was extracted twice with DCM. The organic layers were 
washed twice with H2O, with brine and dried over MgSO4 followed by concentration in vacuo to give 
the crude tosylate 10 which was crystallised from ethanol and gave the desired product as a white 
solid (71.0 g, 200 mmol, 61%).
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 5.88 (d, J = 3.6 Hz, 
1H), 4.51 (d, J = 3.6 Hz, 1H), 4.38 – 4.29 (m, 3H), 4.18 – 4.10 (m, 1H), 2.46 (s, 3H), 2.29 (d, J = 5.0 
Hz, 1H), 1.46 (s, 3H), 1.30 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 145.3, 132.4, 130.0, 128.0, 
112.1, 105.0, 85.0, 77.6, 74.3, 66.1, 26.8, 26.2, 21.7. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. For 
C15H20NaO7S 367.0822 Found 367.0817.
 (3aR,5R,6S,6aR)-5-(azidomethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 11: To a 
stirring solution of tosylate 10 (71.0 g, 210 mmol) in DMF (500 mL) was added NaN3 (33.0 g 520 
mmol). The resulting reaction mixture was stirred at 90°C overnight.  After this, the mixture was 
concentrated in vacuo to give a thick syrup. EtOAc (500 mL) and water (300 mL) were added to the 
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resulting concentrate and the aqueous layer was extracted with EtOAc (2 ). The organic layer was 
dried over MgSO4 and concentrated in vacuo to give 11 (43.0 g, 210 mmol, quant).
1H NMR (400 MHz, CDCl3) δ 5.96 (d, J = 3.7 Hz, 1H), 4.52 (d, J = 3.7 Hz, 1H), 4.34 – 4.22 (m, 2H), 
3.70 – 3.55 (m, 2H), 2.17 (d, J = 4.6 Hz, 1H), 1.51 (s, 3H), 1.32 (s, 3H).13C{1H} NMR (101 MHz, 
CDCl3) δ 112.0, 104.8, 85.3, 78.2, 75.4, 49.2, 26.8, 26.2. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd For 
- C8H13N3NaO4 238.0798 Found: 238.0792.
isobutyl ((3aR,5S,6R,6aR)-5-(azidomethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-
yl)methanesulfonate 15: To a vigorously stirring solution of azide 11 (36.0 g, 170 mmol) in DCM 
(230 mL) was added KBr (2.0 g, 17 mmol) and TEMPO (1.3 g, 8.3 mmol) at room temperature.  The 
resulting mixture was warmed to 30°C and a NaOCl solution (11%-14% active chlorine, 200 mL) was 
slowly added.  The biphasic mixture was stirred for 1 h at 30°C after which 1H NMR of an aliquot of 
the reaction mixture indicated complete conversion of the starting material. The organic layer was 
separated and washed with a KI (1.3 g) solution in 0.5 M HCl (100 mL), a saturated Na2S2O3 solution 
(100 mL) and a saturated NaHCO3 (130 mL) solution. The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo to give crude 12 (36.0g 170mmol) which was used in the next step 
without further purification. To a stirred cooled (0°C) solution of Horner–Wadsworth–Emmons 
reagent 13 (9.5 g, 33 mmol) (Carretero et al.22) in dry THF (250 mL) kept under an N2 atmosphere, 
was added NaH (1.6 g of a 60% suspension in mineral oil, 36 mmol).  The resulting mixture was 
stirred for 30 min at 0°C after which a solution of crude ketone 12 (15.0 g, 30 mmol) in THF (50mL) 
was added dropwise.  The reaction mixture was kept at 0°C for 2 h. Water (50 mL) was then added to 
quench the reaction mixture and it was warmed to room temperature. THF was removed in vacuo and 
the resulting aqueous mixture was diluted with water and extracted with DCM.  The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo to give crude sulfonate 14 
which was dissolved in EtOH (600 mL). To the resulting stirred solution was added NaBH4 (6.8 g, 
180 mmol) in portions over a period of 10 min at 0°C.  The resulting mixture was stirred for 2 h 
at 0°C. AcOH (10mL) was then added to quench the reaction mixture.  The resulting mixture was 
stirred for an additional 15 min at room temperature and the solvent was removed in vacuo.  The 
Page 18 of 42
ACS Paragon Plus Environment






























































obtained solid was partitioned between an aqueous saturated NaHCO3 solution and EtOAc. The 
EtOAc layer was washed with brine dried over MgSO4 filtered and concentrated in vacuo to give 
crude reduced sulfonate 15 which was purified using flash chromatography on silica gel using a 
gradient from 0% to 20% EtOAc in hexanes and gave the desired product as a white solid (6.7 g, 
19 mmol, 48% over three steps).
1H NMR (400 MHz, CDCl3) δ 5.87 (d, J = 3.6 Hz, 1H), 4.84 (t, J = 4.1 Hz, 1H), 4.03 (dd, J = 6.5, 0.7 
Hz, 2H), 3.99 (dt, J = 10.0, 4.0 Hz, 1H), 3.66 (dd, J = 13.4, 3.7 Hz, 1H), 3.56 (dd, J = 14.6, 9.6 Hz, 
1H), 3.41 (dd, J = 13.5, 4.2 Hz, 1H), 3.09 (dd, J = 14.6, 3.5 Hz, 1H), 2.59 (tdd, J = 9.8, 4.6, 3.6 Hz, 
1H), 2.12 – 1.97 (m, 1H), 1.52 (s, 3H), 1.35 (s, 3H), 1.01 (d, J = 1.6 Hz, 3H), 0.99 (d, J = 1.6 Hz, 3H). 
13C{1H} NMR (101 MHz, CDCl3) δ 112.3, 104.8, 80.4, 78.7, 76.1, 51.3, 45.8, 41.1, 28.3, 26.7, 26.4, 
18.7, 18.6, 14.2. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C13H23N3NaO6S 372.1200 Found 
372.1184.
 (2R,3R,4R,5S)-5-(azidomethyl)-4-((isobutoxysulfonyl)methyl)tetrahydrofuran-2,3-diyl diacetate 
16: To a solution of 15 (3.6 g, 10 mmol) in AcOH (60 mL), acetic anhydride (9.1 mL) and a catalytic 
amount (drop) of conc. H2SO4 were added at 0°C.  The resulting mixture was stirred for 6 h at room 
temperature. The reaction mixture was then diluted with DCM (200mL) and slowly poured into an ice 
cold sat. NaHCO3 solution (500 mL).  The organic layer was washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo to give crude 16, which was purified using flash chromatography 
on silica gel using a gradient from 0% to 20% EtOAc in hexanes and gave the desired product as a 
colourless oil, yield (2.6 g, 6.6 mmol, 66%).
1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 5.33 (d, J = 4.8 Hz, 1H), 4.21 (dt, J = 9.2, 4.0 Hz, 1H), 
4.07 – 3.99 (m, 2H), 3.68 (dd, J = 13.4, 4.0 Hz, 1H), 3.50 – 3.34 (m, 2H), 3.16 (dd, J = 14.3, 5.3 Hz, 
1H), 3.14 – 3.06 (m, 1H), 2.14 (s, 3H), 2.12 (s, 5H), 2.10 – 2.01 (m, 1H), 1.01 (s, 4H), 0.99 (s, 3H). 
13C{1H} NMR (101 MHz, CDCl3) δ 169.4, 169.0, 98.2, 82.4, 76.0, 52.5, 46.4, 37.2, 28.3, 21.1, 20.6, 
18.6; HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. For - C14H23N3NaO8S 416.1098 Found 416.1090.
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((isobutoxysulfonyl)methyl)tetrahydrofuran-3-yl acetate 17a: To a stirred solution of 16 (1.7g, 4.3 
mmol) in MeCN (20 mL) was added 6-N-benzoyladenine (2.2 g, 9.0 mmol) and SnCl4 (2.0 mL, 
17 mmol) at 0°C.  The resulting suspension was stirred for 3h at 0 ºC during which the reaction 
mixture became clear.  Next, the reaction mixture was diluted with 50 mL of DCM and quenched with 
an aqueous saturated NaHCO3 solution (50mL) at 0°C. The organic layer was separated and the 
aqueous layer was extracted twice with DCM (2  100 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo to give crude 17a which was purified using flash 
chromatography on silica gel using a gradient of 0% to 10% MeOH in DCM. The desired product was 
obtained as a white foam (1.7 g, 3.1 mmol, 72%).
1H NMR (400 MHz, CDCl3) δ 9.00 (s, 1H), 8.82 (s, 1H), 8.17 (s, 1H), 8.08 – 8.02 (m, 2H), 7.68 – 
7.61 (m, 1H), 7.59 – 7.52 (m, 2H), 6.07 (d, J = 1.0 Hz, 1H), 5.89 (d, J = 5.9 Hz, 1H), 4.36 – 4.27 (m, 
1H), 4.10 (dd, J = 6.5, 2.4 Hz, 2H), 4.00 – 3.91 (m, 1H), 3.82 (dd, J = 13.3, 3.8 Hz, 1H), 3.73 (dd, J = 
13.4, 4.8 Hz, 1H), 3.56 (dd, J = 14.6, 8.9 Hz, 1H), 3.33 (dd, J = 14.6, 5.0 Hz, 1H), 2.23 (s, 3H), 2.15 – 
2.04 (m, 1H), 1.05 (s, 3H), 1.03 (s, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ 169.8, 142.1, 132.9, 
128.9, 127.8, 90.0, 82.4, 77.8, 76.1, 52.0, 46.3, 38.5, 28.4, 20.7, 18.6. HRMS (ESI-TOF) m/z: 
[M+Na]+ Calcd. for – C16H23N5NaO8S 468.1160 Found 468.1168.
(2R,3R,4R,5S)-5-(azidomethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
((isobutoxysulfonyl)methyl)tetrahydrofuran-3-yl acetate 17b: To a stirred solution of 16 (135mg, 
0.34 mmol) in dry MeCN (5 mL) under a nitrogen atmosphere was added uracil (58 mg, 0.51 mmol) 
and N,O-bis(trimethylsilyl)acetamide (290 µL, 1.2 mmol) at room temperature.  The resulting mixture 
was stirred at reflux for 1h and then cooled down to room temperature. TMSOTf (120 µL, 0.69 mmol) 
was added and the resulting mixture was stirred at reflux for 1h.  A sat. NaHCO3 solution (30 mL) 
was added to quench the reaction mixture followed by addition of DCM (30mL). The aqueous layer 
was extracted with DCM (2  30 mL) and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo to give crude 17b which was purified using flash chromatography 
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on silica gel using a 20% to 80% gradient of EtOAc in hexanes and the desired product was obtained 
as a white solid (110 mg, 0.25 mmol, 73%).
1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 7.17 (d, J = 1.2 Hz, 1H), 5.62 (d, J = 2.7 Hz, 1H), 5.54 
(dd, J = 7.1, 2.7 Hz, 1H), 4.18 (dt, J = 8.7, 3.7 Hz, 1H), 4.07 (dd, J = 6.6, 1.0 Hz, 2H), 3.83 (dd, J = 
13.5, 3.2 Hz, 1H), 3.67 (dd, J = 13.5, 4.1 Hz, 1H), 3.47 (dd, J = 14.3, 7.6 Hz, 1H), 3.35 – 3.27 (m, 
1H), 3.18 (dd, J = 14.3, 6.1 Hz, 1H), 2.19 (s, 3H), 2.12 – 2.04 (m, 1H), 1.03 (s, 3H), 1.02 (s, 
3H).13C{1H} NMR (101 MHz, CDCl3) δ 169.6, 162.5, 149.7, 140.9, 103.2, 92.2, 81.4, 76.6, 76.2, 
51.9, 46.7, 37.7, 28.4, 20.6, 18.6. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – C24H28N8NaO7S 
595.1680 Found 595.1694.
(2R,3R,4R,5S)-2-(2-acetamido-6-((diphenylcarbamoyl)oxy)-9H-purin-9-yl)-5-(azidomethyl)-4-
((isobutoxysulfonyl)methyl)tetrahydrofuran-3-yl acetate 17e: To a stirring suspension of 2-N-
acetyl-6-O-diphenylcarbamoylguanine (990 mg 2.54 mmol) in DCE (7 mL) was added N,O-
Bis(trimethyl)acetamide (1.20 mL, 5.08 mmol). The resulting suspension was refluxed for 10 min and 
then cooled down to room temperature.  A solution of compound 16 (500 mg, 1.24 mmol) in DCE 
(3 mL) was added to the reaction mixture.  TMSOTf (0.43 mL, 2.5 mmol) was then added dropwise at 
0°C, and thereafter the reaction mixture was refluxed for 1h, the reaction was quenched at 0°C with 
saturated aqueous NaHCO3 (5 mL), diluted in DCM (20 mL) and the organic layer was separated. The 
aqueous layer was extracted with DCM (3  20 mL) and the combined organic layers were washed 
with sat. NaHCO3 (20 mL) and brine (3  20 mL), dried over MgSO4 and concentrated in vacuo. The 
crude, obtained as a yellow foam, was purified by column chromatography using a gradient of 0% to 
5% of MeOH in DCM to give the desired product 17e as a white foam (330 mg, 0.46mmol, 36%).
1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 8.02 (s, 1H), 7.44 – 7.35 (m, 8H), 5.90 (s, 1H), 5.81 (d, J 
= 5.3 Hz, 1H), 4.22 (m, 1H), 4.04 (tt, J = 9.4, 4.8 Hz, 2H), 3.76 (t, J = 4.4 Hz, 2H), 3.52 (dd, J = 14.4, 
9.6 Hz, 1H), 3.33 (dd, J = 14.4, 4.3 Hz, 1H), 2.39 (s, 3H), 2.13 (d, J = 9.7 Hz, 1H), 0.97 (d, J = 7.0, 
6H). 13C{1H} NMR (101 MHz, CDCl3) δ 171.1, 169.8, 156.5, 153.8, 151.9, 150.2, 143.1, 121.5, 90.0, 
82.3, 77.7, 76.1, 60.4, 52.1, 46.2, 38.4, 28.3, 25.1, 21.0, 20.6, 18.6, 18.6, 14.2. HRMS (ESI-TOF) m/z: 
[M+Na]+ Calcd. for – C32H35N9NaO9S 744.2150 Found 744.2171.
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((isobutoxysulfonyl)methyl)tetrahydrofuran-3-yl acetate 17d: To a stirring suspension of N4-
Benzoylcytosine (500 mg, 2.30 mmol) in  (5 mL) was added (NH4)2SO4 (2.1 mg).  This suspension 
was refluxed for 3 h, until a clear solution was obtained.  The mixture was concentrated and co-
evaporated three times with toluene, and a solution of 16 (400 mg, 1.01 mmol) in DCE (4 mL) was 
added to the residue.  TMSOTf (0.36 mL, 2.02 mmol) was then added dropwise at 0°C, and the 
reaction mixture was refluxed for 1h. The reaction was quenched at 0°C with saturated aqueous 
NaHCO3 (5 mL), diluted with DCM (20 mL) and organic layer was separated. The aqueous layer was 
extracted with DCM (3  20 mL) and the combined organic layers were washed with saturated 
aqueous NaHCO3 (60 mL) and brine (3  60 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product, obtained as a yellow foam, was purified by silica gel column chromatography using a 
gradient 0% to 5% MeOH in DCM to give the desired product 17d as a white foam (410 mg, 0.74 
mmol, 74%). 
1H NMR (400 MHz, Chloroform-d) δ 8.69 (s, 1H), 7.98 – 7.87 (m, 3H), 7.66 – 7.59 (m, 1H), 7.55 – 
7.48 (m, 2H), 5.72 (d, J = 2.1 Hz, 1H), 5.65 (dd, J = 6.6, 2.1 Hz, 1H), 4.26 (dt, J = 9.0, 3.7 Hz, 2H), 
4.04 (dd, J = 6.5, 1.4 Hz, 2H), 3.89 (dd, J = 13.4, 3.2 Hz, 1H), 3.81 (dd, J = 13.5, 4.3 Hz, 1H), 3.48 
(dd, J = 14.4, 6.6 Hz, 1H), 3.39 – 3.26 (m, 1H), 3.18 (dd, J = 14.4, 6.7 Hz, 1H), 2.17 (s, 3H), 2.12 – 
1.99 (m, 1H), 1.00 (s, 3H), 0.99 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 169.6, 133.3, 129.1, 
93.5, 82.3, 76.4, 52.0, 46.9, 37.7, 28.3, 20.7, 18.6. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – 
C23H28N6NaO8S 571.1582 Found 571.1581.
(2R,3R,4R,5S)-2-(2-acetamido-6-oxo-1H-purin-9(6H)-yl)-5-(azidomethyl)-4-
((isobutoxysulfonyl)methyl)tetrahydrofuran-3-yl acetate 17c: Compound 17e (330 mg 0.45 mmol) 
was dissolved in a solution of 1:1 DCM:TFA (5 mL) and stirred at room temperature for 1 h after 
which it was concentrated in vacuo. The residue was dissolved in DCM, washed with an aqueous 
saturated NaHCO3 (20 mL) solution, brine (3  20 mL), dried over MgSO4 and concentrated in vacuo.  
The crude product was obtained as a yellow foam and purified by column chromatography using a 
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gradient of 0% to 5% MeOH in DCM to give the desired product 17c as a white foam (200 mg, 0.38 
mmol, 85%).
1H NMR (400 MHz, CDCl3) δ 11.84 (s, 1H), 9.04 (s, 1H), 7.73 (s, 1H), 6.13 (d, J = 4.7 Hz, 1H), 5.80 
(s, 1H), 4.39 (s, 1H), 4.21 (dt, J = 10.6, 4.1 Hz, 1H), 4.11 – 4.00 (m, 2H), 3.64 (dd, J = 13.5, 4.1 Hz, 
1H), 3.52 (dd, J = 14.1, 10.6 Hz, 1H), 3.42 (dd, J = 13.5, 4.0 Hz, 1H), 3.26 (dd, J = 14.1, 3.0 Hz, 1H), 
2.25 (s, 3H), 2.19 (s, 3H), 2.11 – 1.99 (m, 1H), 1.00 (s, 3H), 0.99 (s, 3H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 171.6, 169.7, 155.3, 147.1, 146.8, 139.2, 121.8, 89.5, 81.3, 76.5, 51.5, 45.6, 38.3, 28.3, 24.2, 
20.7, 18.6. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C32H35N9NaO9S 744.2150; Found 744.2171. 
tetrabutylammonium ((2S,3R,4R,5R)-4-acetoxy-2-(azidomethyl)-5-(6-benzamido-9H-purin-9-
yl)tetrahydrofuran-3-yl)methanesulfonate 18a: To a stirred solution of 17a (110 mg, 0.53 mmol) in 
10 mL of acetone was added TBAI (300 mg, 0.80 mmol). The resulting solution was stirred at reflux 
for 22 h after which LC/MS analysis showed completion of the reaction. Next, the solvent was 
removed in vacuo and the crude mixture was purified using a gradient of 0% to 15% MeOH in DCM 
affording the desired product 18a as a white foam (370 mg, 0.49 mmol, 92%).
1H NMR (400 MHz, CDCl3) δ 9.15 (s, 1H), 8.81 (s, 1H), 8.43 (s, 1H), 8.01 (d, J = 7.6 Hz, 2H), 7.59 
(d, J = 7.3 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 6.18 (d, J = 1.5 Hz, 1H), 5.85 (d, J = 5.9 Hz, 1H), 4.53 – 
4.40 (m, 1H), 4.08 – 3.84 (m, 1H), 3.36 (s, 1H), 3.32 – 3.22 (m, 8H), 3.17 (dd, J = 13.8, 6.0 Hz, 1H), 
2.95 (dd, J = 13.8, 7.8 Hz, 1H), 2.13 (s, 3H), 1.70 – 1.57 (m, 8H), 1.53 – 1.34 (m, 8H), 0.98 (t, J = 7.3 
Hz, 12H). 13C{1H} NMR (101 MHz, CDCl3) δ 169.9, 164.6, 152.8, 151.4, 149.4, 141.6, 133.7, 132.7, 
128.8, 127.8, 123.1, 88.4, 83.9, 78.7, 58.8, 52.8, 47.5, 39.4, 24.0, 20.8, 19.7, 13.6. HRMS (ESI-TOF) 
m/z: [M-H]- Calcd. for - C20H19N8O7S 515.1080; Found 515.1103. 
tetrabutylammonium ((2S,3R,4R,5R)-4-acetoxy-2-(azidomethyl)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)methanesulfonate 18b: Compound 17b was 
synthesized according to the procedure used for the preparation of 18a. Purification by flash 
chromatography on silica gel using a 0% to 15% gradient of MeOH in DCM gave the desired product 
9a as a white foam (150 mg, 0.24 mmol, 96%).
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1H NMR (400 MHz, , CDCl3) δ 8.81 (s, 1H), 7.64 (d, J = 8.1 Hz, 1H), 5.88 (d, J = 2.5 Hz, 1H), 5.73 
(d, J = 8.1 Hz, 1H), 5.47 (dd, J = 6.9, 2.6 Hz, 1H), 4.38 – 4.30 (m, 1H), 3.97 (dd, J = 13.3, 2.7 Hz, 
1H), 3.91 (dd, J = 13.4, 4.2 Hz, 1H), 3.36 – 3.22 (m, 8H), 3.10 (dd, J = 13.6, 5.1 Hz, 1H), 3.06 – 2.96 
(m, 1H), 2.84 (dd, J = 13.6, 8.0 Hz, 1H), 2.09 (s, 3H), 1.72 – 1.59 (m, 8H), 1.53 – 1.39 (m, 8H), 1.01 
(t, J = 7.3 Hz, 12H). 13C{1H} NMR (101 MHz, CDCl3) δ 169.5, 162.9, 149.9, 140.1, 102.7, 89.1, 82.8, 
77.6, 58.8, 52.7, 47.6, 39.1, 24.0, 20.7, 19.7, 13.7. HRMS (ESI-TOF) m/z: [M-H]- Calcd. for - 
C12H14N5O8S 388.0569; Found 388.0564.
tetrabutylammonium ((2S,3R,4R,5R)-4-acetoxy-2-(azidomethyl)-5-(4-benzamido-2-
oxopyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)methanesulfonate 18c: Compound 18c was 
synthesized according to the procedure used for the preparation of 18a. Purification by flash 
chromatography on silica gel using a gradient from 0% to 15% MeOH in DCM gave the desired 
product 18c as a white foam (230 mg, 0.32 mmol, 94%).
1H NMR (400 MHz, CDCl3) δ 11.81 (s, 1H), 11.35 (s, 1H), 7.62 (s, 1H), 6.36 (d, J = 4.4 Hz, 1H), 
5.76 (s, 1H), 4.67 – 4.57 (m, 1H), 4.19 (ddd, J = 11.2, 6.3, 2.5 Hz, 1H), 3.64 (dd, J = 13.5, 2.6 Hz, 
1H), 3.40 – 3.15 (m, 8H), 2.84 (dd, J = 13.7, 2.9 Hz, 1H), 2.27 (s, 3H), 2.14 (s, 3H), 1.74 – 1.60 (m, 
8H), 1.52 – 1.36 (m, 8H), 0.99 (t, J = 7.3 Hz, 12H). 13C{1H} NMR (101 MHz, CDCl3) δ 173.2, 170.5, 
156.0, 147.7, 147.4, 139.2, 121.2, 89.7, 82.9, 78.3, 58.9, 52.8, 45.7, 40.0, 24.2, 23.9, 20.9, 19.7, 13.6. 
HRMS (ESI-TOF) m/z: [M-H]- Calcd. for - C15H17N8O8S 469.0896; Found 469.0891.
tetrabutylammonium ((2S,3R,4R,5R)-4-acetoxy-2-(azidomethyl)-5-(4-benzamido-2-
oxopyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)methanesulfonate 18d: Compound 18d was 
synthesized according to the procedure used for the preparation of 18a. Purification by flash 
chromatography on silica gel using a gradient from 0% to 15% MeOH in DCM gave the desired 
product 18d as a white foam (260 mg, 0.36 mmol, 92%).
1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.27 (s, 1H), 7.92 (d, J = 7.6 Hz, 2H), 7.68 – 7.43 (m, 
3H), 5.97 (s, 1H), 5.60 (d, J = 5.6 Hz, 1H), 4.50 – 4.38 (m, 1H), 4.22 – 3.99 (m, 2H), 3.39 – 3.27 (m, 
8H), 3.10 (dd, J = 13.7, 3.9 Hz, 1H), 3.04 – 2.92 (m, 1H), 2.83 (dd, J = 13.7, 9.0 Hz, 1H), 2.17 (s, 
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2H), 2.10 (s, 3H), 1.74 – 1.59 (m, 8H), 1.56 – 1.37 (m, 8H), 1.01 (t, J = 7.3 Hz, 12H). 13C{1H} NMR 
(101 MHz, Chloroform-d) δ 169.2, 133.1, 129.0, 83.7, 78.3, 58.9, 52.7, 47.9, 38.8, 30.9, 24.1, 20.8, 
19.8, 13.7. HRMS (ESI-TOF) m/z: [M-H]- Calcd. for - C19H19N6O8S 491.0991; Found 491.0969.
(2R,3R,4R,5S)-5-(azidomethyl)-2-(6-benzamido-9H-purin-9-yl)-4-
(((perfluorophenoxy)sulfonyl)methyl)tetrahydrofuran-3-yl acetate 20a: To a stirred solution of 
compound 18a (760 mg, 1.00 mmol) in acetonitrile (10 mL) was added POCl3 (470 µL, 5.00 mmol) at 
0°C. The resulting mixture was stirred at room temperature for 6h. The mixture was then concentrated 
in vacuo to give crude 19a as a foam, which was dissolved in dry DCM (10 mL) under a N2 
atmosphere. To this stirred, cooled (0°C) solution were added PFPOH (740 mg, 4.00 mmol) and 
NMM (440 µL, 4.00 mmol).  Then, the mixture was warmed to room temperature and stirred for an 
additional 1h. The reaction mixture was diluted with DCM (40 mL) and quenched with 1 M HCl (10 
mL).  The organic layer was separated and the aqueous layer was extracted twice with DCM.  The 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give 
crude 20a which was purified by flash chromatography on silica gel using a gradient from 0% to 10% 
MeOH in DCM affording the desired product as a white foam (560 mg, 0.82 mmol, 82%).
1H NMR (400 MHz, CDCl3) δ 8.92 (s, 1H), 8.81 (s, 1H), 8.14 (s, 1H), 8.03 (d, J = 7.7 Hz, 2H), 7.62 
(t, J = 7.2 Hz, 1H), 7.54 (t, J = 7.7 Hz, 2H), 6.06 (s, 1H), 5.92 (d, J = 5.9 Hz, 1H), 4.33 (dt, J = 9.2, 
4.5 Hz, 1H), 4.24 – 4.15 (m, 1H), 3.92 (dd, J = 14.6, 9.4 Hz, 1H), 3.83 (dd, J = 13.3, 4.4 Hz, 1H), 3.78 
(d, J = 4.8 Hz, 1H), 3.73 (dd, J = 14.3, 4.4 Hz, 1H), 2.22 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 
169.7, 164.6, 152.8, 151.1, 149.9, 142.1, 133.5, 132.9, 128.9, 127.9, 123.6, 90.1, 82.0, 77.6, 53.5, 
51.9, 48.6, 38.7, 20.5. 19F NMR (376 MHz, CDCl3) δ -150.85 – -151.65 (m), -153.65 – -154.50 (m), -
159.64 – -160.59 (m). HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C26H19F5N8NaO7S 705.0916; 
Found 705.0906.
 (2R,3R,4R,5S)-5-(azidomethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
(((perfluorophenoxy)sulfonyl)methyl)tetrahydrofuran-3-yl acetate 20b: Compound 20b was 
synthesized according to the procedure used for the preparation of 20a. Purification by flash 
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chromatography on silica gel using a gradient from 0% to 10% of MeOH in DCM gave the desired 
product 11b as a white foam yield (95 mg, 0.17 mmol, 95%).
1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.1 Hz, 1H), 5.81 (dd, J = 8.1, 1.8 Hz, 1H), 5.60 (dd, J = 
6.8, 2.3 Hz, 1H), 5.56 (d, J = 2.3 Hz, 1H), 4.20 (dt, J = 8.3, 4.1 Hz, 1H), 3.90 – 3.80 (m, 2H), 3.71 
(dd, J = 13.4, 4.4 Hz, 1H), 3.65 – 3.51 (m, 2H), 2.19 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 
169.7, 149.8, 141.5, 103.2, 93.5, 81.2, 76.5, 51.9, 49.1, 38.1, 20.5. 19F NMR (376 MHz, CDCl3) δ -
150.75 – -151.58 (m), -159.71 – -160.44 (m), -159.72 – -160.65 (m). HRMS (ESI-TOF) m/z: 
[M+Na]+ Calcd. for - C18H14F5N5NaO8S 578.0381; Found 578.0379.
(2R,3R,4R,5S)-2-(2-acetamido-6-oxo-1H-purin-9(6H)-yl)-5-(azidomethyl)-4-
(((perfluorophenoxy)sulfonyl)methyl)tetrahydrofuran-3-yl acetate 20c: Compound 20c was 
synthesized according to the procedure used for the preparation of 20a. Purification by flash 
chromatography on silica gel using a gradient from 0% to 15% MeOH in DCM gave the desired 
product 20c as a white foam (120 mg, 0.19 mmol, 60%).
1H NMR (400 MHz, CDCl3) δ 11.86 (s, 1H), 8.67 (s, 1H), 7.69 (s, 1H), 6.20 (d, J = 4.8 Hz, 1H), 5.82 
(s, 1H), 4.46 (t, J = 10.5 Hz, 0H), 4.27 (dt, J = 9.9, 4.4 Hz, 1H), 3.92 (dd, J = 14.4, 10.6 Hz, 1H), 3.76 
– 3.64 (m, 2H), 3.51 (dd, J = 13.5, 3.9 Hz, 1H), 2.25 (s, 3H), 2.20 (s, 3H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 171.4, 169.6, 155.3, 147.1, 146.8, 139.0, 122.2, 89.6, 80.8, 76.2, 51.5, 48.2, 38.7, 24.2, 20.5. 
19F NMR (376 MHz, CDCl3) δ -151.78 – -151.93 (m), -153.14 – -153.40 (m), -159.55 – -159.84 (m). 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – C21H17F5N8NaO8S 659.0702; Found 659.0702.
(2R,3R,4R,5S)-5-(azidomethyl)-2-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-
(((perfluorophenoxy)sulfonyl)methyl)tetrahydrofuran-3-yl acetate 20d: Compound 20d was 
synthesized according to the procedure used for the preparation of 20a. Purification by flash 
chromatography on silica gel using a gradient from 0% to 10% of MeOH in DCM gave the desired 
product 20d as a white foam (190 mg, 0.29 mmol, 57%).
1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 7.5 Hz, 2H), 7.86 (d, J = 7.5 Hz, 1H), 7.66 – 7.58 (m, 2H), 
7.52 (t, J = 7.6 Hz, 2H ), 5.72 (dd, J = 6.3, 2.0 Hz, 1H), 5.68 (d, J = 2.0 Hz, 1H), 4.28 (dd, J = 8.3, 3.9 
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Hz, 1H), 3.94 – 3.77 (m, 3H), 3.66 – 3.54 (m, 2H), 2.18 (s, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 
169.6, 133.3, 129.1, 127.6, 94.6, 82.0, 77.1, 52.1, 49.4, 38.1, 20.6; 19F NMR (376 MHz, CDCl3) δ -
150.91 – -151.27 (m), -154.11 – -154.48 (m), -159.96 – -160.46 (m). HRMS (ESI-TOF) m/z: 
[M+Na]+ Calcd. for – C25H19F5N6NaO8S 681.0797; Found 681.0797. 
(2R,3R,4R,5S)-5-(azidomethyl)-4-((N,N-dimethylsulfamoyl)methyl)-2-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl acetate 21: To a solution of 20b (160 mg, 0.28 
mmol) in acetonitrile (5 mL) was added dimethyl amine (560 µL, 0.56 mmol).  The resulting mixture 
was stirred for 1h at room temperature and then concentrated in vacuo to give crude 21 which was 
purified by flash chromatography on silica gel using a gradient of 0% to 10% MeOH in DCM 
affording 21 as a white foam (120 mg, 0.28 mmol, quant).
1H NMR (400 MHz, CDCl3) δ 8.58 (s, 1H), 7.39 (d, J = 8.1 Hz, 1H), 5.78 (d, J = 8.1 Hz, 1H), 5.61 (s, 
1H), 5.57 – 5.49 (m, 1H), 4.18 (dt, J = 7.2, 3.4 Hz, 1H), 3.83 (dd, J = 13.5, 2.8 Hz, 1H), 3.69 (dd, J = 
13.5, 3.9 Hz, 1H), 3.29 – 3.15 (m, 2H), 2.98 – 2.92 (m, 1H), 2.92 (s, 6H), 2.16 (s, 3H); 13C{1H} NMR 
(101 MHz, CDCl3) δ 169.7, 162.5, 149.8, 1401.0, 103.2, 92.0, 81.7, 76.8, 52.0, 44.5, 37.5, 37.4, 20.7. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – C14H20N6NaO7S 439.1006; Found 439.1008. 
Sa-dinucleotide-compound 23:  To a solution of 21 (120 mg, 0.28 mmol) in MeOH (5 mL) was added 
10% Pd/C (60 mg). The resulting suspension was stirred for 1 h at room temperature under an H2 
atmosphere (balloon). The resulting suspension was filtered over Celite and the filtrate was 
concentrated in vacuo to give crude amine 22, which used in the next step without further purification. 
After dissolving crude 22 in DMF (2 mL). To the resulting solution was added PFP-ester 20a 
(200 mg, 0.30 mmol) and DiPEA (80 µL, 0.56mmol).  The resulting mixture was stirred for 4h at 
room temperature under a N2 atmosphere followed by concentration in vacuo to give crude 23 which 
was purified by flash chromatography on silica gel using a gradient from 0% to 5% MeOH in DCM 
and the desired product was obtained as a white foam (150 mg, 0.17 mmol, 60%).
LC/MS: tR – 5.39min, [M]+ m/z – 888.92, 10 min run.
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Sa-trinucleotide compound 24: To a solution of dinucleotide 23 (140mg, 0.16 mmol) in MeOH 
(5 mL) was added 10% Pd/C (50 mg).  The resulting suspension was stirred overnight at room 
temperature under a H2 atmosphere (balloon). The resulting suspension was filtered over Celite and 
the filtrate was concentrated in vacuo to give the crude amino sa-dinucleotide product as a foam 
which used in the next step without further purification. After dissolving in DMF (5 mL) and addition 
of PFP-ester 20b (177 mg, 0.32 mmol) and DiPEA (93 µL, 0.64mmol), the resulting mixture was 
heated to 70°C under microwave irradiation and stirred for 20 min. The reaction mixture was then 
concentrated in vacuo to give the crude 24 which was purified by flash chromatography on silica gel 
using a gradient from 0% to 20% MeOH in DCM and the desired product was obtained as a white 
foam (72 mg, 0.06 mol, 36%).
LC/MS: tR – 5.31min, [M]+ m/z – 1233.92, 10 min run.
Sa-tetranucleotide compound 26: To a solution of 24 (72 mg, 58 µmol) in THF (5 mL) was added 
10% Pd/C (50 mg). The resulting suspension was stirred overnight at room temperature under a H2 
atmosphere (balloon).  Next, the resulting suspension was filtered over Celite and the filtrate was 
concentrated in vacuo to give the crude amino sa-trinucleotide product as a foam which used in the 
next step without further purification.  After dissolution in DMF (2 mL), PFF-ester 20a (82 mg, 120 
µmol) and DiPEA (60 µL 350 µmol) were added.  The mixture was heated to 85°C under microwave 
irradiation and stirred for 15 min.  Next, the reaction mixture was concentrated in vacuo to give crude 
protected tetranucleoride 25, which was dissolved in 7N ammonia in methanol.  The resulting mixture 
was stirred overnight at room temperature.  The reaction mixture was then concentrated in vacuo to 
give crude 26. Crude 26 was purified by preparative HPLC to give >95% pure (by HPLC) 26 (5.4 mg, 
4.1 µmol, 7% yield over two steps).
LC/MS: tR – 9.07min, [M]+ m/z – 1330.17, 40 min run.
HPLC: tR – 5.85min.
(2R,3R,4R,5S)-5-(azidomethyl)-2-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-((N-
isobutylsulfamoyl)methyl)tetrahydrofuran-3-yl acetate 27: Compound 27 was synthesized 
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according to the procedure used for the preparation of 21. Purification by flash chromatography on 
silica gel using a gradient from 0% to 5% MeOH in DCM gave the desired product 27 as a white 
foam (110 mg, 0.20 mmol, 87%).
1H NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 7.94 (t, J = 7.3 Hz, 3H), 7.66 – 7.48 (m, 4H), 5.80 (d, J = 
6.2 Hz, 1H), 5.68 (d, J = 1.7 Hz, 1H), 4.21 (dt, J = 8.5, 3.8 Hz, 1H), 3.82 (d, J = 3.9 Hz, 2H), 3.38 (dd, 
J = 14.4, 7.1 Hz, 1H), 3.32 – 3.19 (m, 1H), 3.01 (dd, J = 14.4, 5.4 Hz, 1H), 2.94 – 2.89 (m, 2H), 2.14 
(s, 3H), 1.86 – 1.73 (m, 1H), 0.94 (s, 3H), 0.92 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 169.8, 
133.2, 129.00, 127.8, 93.9, 82.4, 77.5, 51.8, 50.6, 47.9, 38.0, 29.0, 20.8, 19.8, 19.8. HRMS (ESI-TOF) 
m/z: [M+Na]+ Calcd. for – C23H29N7NaO7S 570.1732; Found 570.1741.
Compound 29: Compound 29 was synthesized according to the procedure used for the preparation of 
22. Purification by flash chromatography on silica gel using a gradient from 0% to 15% MeOH in 
DCM gave the desired product 22 as a white foam (120 mg,  0.12 mmol, 62%).
1H NMR (400 MHz, CDCl3) δ 12.02 (s, 1H), 9.54 (s, 2H), 8.11 (s, 1H), 8.09 (s, 1H), 7.88 (s, 1H), 
7.67 – 7.47 (m, 4H), 5.93 (s, 1H), 5.75 (s, 1H), 5.58 (d, J = 6.8 Hz, 1H), 4.24 – 4.07 (m, 2H), 3.73 (d, 
J = 13.3 Hz, 1H), 3.65 – 3.32 (m, 6H), 3.21 (d, J = 14.2 Hz, 1H), 3.08 (d, J = 12.8 Hz, 1H), 3.01 – 
2.85 (m, 2H), 2.26 (s, 3H), 2.13 (s, 3H), 2.09 (s, 3H), 1.95 (s, 2H), 1.85 – 1.72 (m, 1H), 0.93 (s, 3H), 
0.92 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 170.3, 169.9, 147.2, 133.4, 129.00, 50.6, 29.0, 20.7, 
19.9, 19.8. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C38H47N13NaO14S2 996.2699; Found 
996.2678.
Compound 30: Compound 30 was synthesized according to the procedure used for the preparation of 
26. Purification by preparative HPLC gave the desired product 30 as a white foam (20 mg,  27 µmol, 
23%).
1H NMR (400 MHz, Methanol-d4) δ 8.22 (s, 2H), 8.20 (s, 1H), 6.08 (d, J = 7.9 Hz, 1H), 5.93 (s, 1H), 
5.68 (s, 1H), 4.78 (d, J = 5.1 Hz, 1H), 4.61 – 4.54 (m, 1H), 4.31 – 4.23 (m, 1H), 4.22 – 4.15 (m, 1H), 
3.87 (dd, J = 13.8, 2.8 Hz, 1H), 3.74 (dd, J = 13.8, 4.0 Hz, 1H), 3.70 – 3.57 (m, 2H), 3.52 – 3.42 (m, 
2H), 3.29 – 3.24 (m, 1H), 3.12 (dd, J = 14.3, 4.5 Hz, 1H), 3.03 – 2.94 (m, 1H), 2.88 (d, J = 1.1 Hz, 
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1H), 2.86 (d, J = 1.0 Hz, 1H), 2.53 – 2.43 (m, 1H), 1.83 – 1.68 (m, 1H), 0.94 (s, 3H), 0.92 (s, 3H). 
13C{1H} NMR (101 MHz, Methanol-d4) δ 160.2, 157.2, 154.3, 147.5, 144.7, 136.3, 135.8, 128.5, 
115.0, 94.1, 93.0, 91.3, 83.0, 81.9, 75.1, 75.0, 51.1, 50.0, 48.2, 48.1, 48.0, 47.9, 47.8, 47.7, 47.6, 47.5, 
47.4, 47.2, 47.0, 46.6, 43.3, 38.6, 38.5, 28.9, 18.9. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for 
C25H38N13O10S2 743.2284; Found: 743.2301.
isobutyl ((3aR,5S,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethylfuro[2,3-
d][1,3]dioxol-6(3aH,5H,6aH)-ylidene)methanesulfonate 33: Diacetone-D-glucose 31 (45g, 170 
mmol) was oxidized to the corresponding ketone 32 in an analogous procedure to that described for 
12 to give crude ketone 32 (40 g 150 mmol) which was used in the next step without further 
purification. As described in literature (Blade et al.21). To a stirred solution of Horner–Wadsworth–
Emmons reagent 13 (18g, 64 mmol) in dry THF (400 mL) kept under N2 atmosphere was added NaH 
(2.6 g, 60% in mineral oil, 64 mmol) at 0°C.  The resulting mixture was stirred for 30 min at 0°C after 
which a solution of crude ketone 32 (15 g, 58 mmol) in THF (100 mL) was added drop wise. The 
reaction mixture was kept at 0°C for 2h.  Water (100 mL) was then added and the quenched reaction 
mixture was warmed to room temperature. THF was removed in vacuo, additional water (200 mL) 
was added and mixture was extracted with DCM (3  500mL).  The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo to give crude 33 which was purified by flash 
chromatography on silica gel using a gradient of 0% to 40% EtOAc in hexanes and the desired 
product was obtained as a white solid as a 1:1 mixture of E/Z isomers (16 g, 41 mmol, 72%, the 
overall yield over two steps was 65%).
1H NMR (400 MHz, CDCl3) δ 6.83 – 6.81 (m, 1H), 6.56 (t, J = 1.8 Hz, 1H), 5.96 (d, J = 4.8 Hz, 1H), 
5.87 (d, J = 4.1 Hz, 1H), 5.68 (dt, J = 4.4, 1.3 Hz, 2H), 5.17 (d, J = 4.7 Hz, 1H), 4.66 (dt, J = 8.2, 1.5 
Hz, 1H), 4.32 – 4.26 (m, 1H), 4.17 – 4.09 (m, 1H), 4.07 – 3.98 (m, 6H), 3.92 (dd, J = 9.3, 6.5 Hz, 
1H), 3.77 (dd, J = 9.2, 7.8 Hz, 1H), 2.11 – 1.98 (m, 2H), 1.51 (s, 3H), 1.46 – 1.45 (m, 4H), 1.45 – 1.44 
(m, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.35 (s, 3H), 1.34 (s, 3H), 1.34 (s, 3H), 0.99 (s, 3H), 0.99 (d, J = 
1.3 Hz, 4H), 0.98 (s, 3H), 0.97 (d, J = 1.2 Hz, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 156.0, 154.5, 
122.3, 122.0, 114.3, 113.3, 110.4, 109.5, 105.0, 103.7, 82.2, 79.7, 79.0, 78.7, 76.3, 67.5, 65.4, 28.2, 
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28.2, 28.0, 27.8, 27.3, 27.0, 26.8, 26.0, 25.6, 25.3, 18.7, 18.6, 18.6, 18.6. HRMS (ESI-TOF) m/z: 
[M+Na]+ Calcd. for – C17H28NaO8S 415.1378; Found 415.1397. 
isobutyl ((3aR,5S,6R,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-yl)methanesulfonate  34: To a stirred solution of 33 
(34 g, 87 mmol) in EtOH (2 L) was added NaBH4 (20 g, 520 mmol) over 10 min at 0°C. The resulting 
mixture was stirred for 2h at 0°C.  Glacial AcOH (14 mL) was then added to quench the reaction 
mixture and the resulting mixture was stirred for 15 min at room temperature after which the solvent 
was removed in vacuo.  The obtained solid was partitioned between a sat. NaHCO3 solution (500 mL) 
and EtOAc (500 mL).  The organic layer was washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo to give 34 (34 g, 87 mmol, quant).
1H NMR (400 MHz, CDCl3) δ 5.85 (d, J = 3.6 Hz, 1H), 4.85 (t, J = 4.1 Hz, 1H), 4.03 (dd, J = 6.5, 0.9 
Hz, 2H), 3.97 – 3.86 (m, 2H), 3.76 – 3.64 (m, 1H), 3.58 (dd, J = 14.6, 9.9 Hz, 1H), 3.12 (dd, J = 14.6, 
3.2 Hz, 1H), 2.64 (tdd, J = 9.9, 4.6, 3.2 Hz, 1H), 2.04 (dq, J = 13.4, 6.7 Hz, 1H), 1.83 (dd, J = 7.7, 5.0 
Hz, 1H), 1.52 (s, 3H), 1.35 (s, 3H), 1.01 (d, J = 1.7 Hz, 3H), 0.99 (d, J = 1.7 Hz, 3H). 13C{1H} NMR 
(101 MHz, CDCl3) δ 112.3, 110.0, 105.2, 80.3, 79.9, 77.9, 76.2, 68.3, 45.1, 44.6, 28.3, 26.8, 26.7, 
26.4, 25.1, 18.7, 18.7. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – C17H30NaO8S 417.1550; Found 
417.1554. 
isobutyl ((3aR,5S,6R,6aR)-5-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-
yl)methanesulfonate 35: Compound 34 (34g, 86 mmol) was dissolved in a mixture of glacial acetic 
acid (160 mL), water (80 mL) and MeOH (80 mL), and then stirred overnight at 50°C. Next, the 
reaction mixture was concentrated in vacuo and co-evaporated twice with toluene.  The obtained 
crude diol 35 was dissolved in MeOH (260 mL) and a solution of NaIO4 (22 g, 100 mmol) in water 
(60mL) was added at room temperature. The resulting mixture was stirred for 15 min at room 
temperature, after which it was concentrated in vacuo.  The resulting solid was suspended in water 
(200 mL) and extracted with CHCl3 (3  400mL).  The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The resulting crude aldehyde was dissolved in a mixture 
of MeOH (280 mL) water (70 mL) and NaBH4 (2.7g, 100 mmol) was added over 10 min at 0°C.  The 
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reaction mixture was warmed to room temperature and stirred for 30 min after which MeOH was 
evaporated and the resulting reaction mixture extracted three times with EtOAc (3  300 mL). The 
combined organic layers were washed with brine and dried over MgSO4, filtered and concentrated in 
vacuo to give crude 23 which was purified by flash chromatography on silica gel using a 0% to 50% 
EtOAc gradient in hexanes. Desired Alcohol 36 was obtained as a white solid (15.0 g, 46 mmol, 
54%).
1H NMR (400 MHz, CDCl3) δ 5.85 (d, J = 3.6 Hz, 1H), 4.85 (t, J = 4.1 Hz, 1H), 4.03 (dd, J = 6.5, 0.9 
Hz, 2H), 3.97 – 3.86 (m, 2H), 3.76 – 3.64 (m, 1H), 3.58 (dd, J = 14.6, 9.9 Hz, 1H), 3.12 (dd, J = 14.6, 
3.2 Hz, 1H), 2.64 (tdd, J = 9.9, 4.6, 3.2 Hz, 1H), 2.04 (dq, J = 13.4, 6.7 Hz, 1H), 1.83 (dd, J = 7.7, 5.0 
Hz, 1H), 1.52 (s, 3H), 1.35 (s, 3H), 1.01 (d, J = 1.7 Hz, 3H), 0.99 (d, J = 1.7 Hz, 3H). 13C{1H} NMR 
(101 MHz, CDCl3) δ 112.2, 104.9, 80.5, 80.2, 76.1, 61.3, 45.8, 39.6, 28.3, 26.7, 26.4, 18.7, 18.7. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C13H24NaO7S 347.1140; Found 347.1135.
((3aR,5S,6R,6aR)-6-((isobutoxysulfonyl)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-
5-yl)methyl 4-oxopentanoate 37: To a solution of 36 (560 mg, 1.7 mmol) in DCM (70 mL) were 
added levulinic acid (400 mg, 3.5 mmol), EDC HCl (500 mg, 2.6 mmol), DMAP (100 mg, 
0.85 mmol) and DiPEA (890 µL, 5.1 mmol).  After stirring for 16h the reaction mixture was diluted 
with DCM (30 mL) and this organic layer was washed with 1 M HCl (20 mL), a saturated NaHCO3 
solution (20 mL) and brine (20 mL).  After drying over MgSO4, filtering and concentration in vacuo 
crude 37 was obtained which was purified by flash chromatography on silica gel using a gradient of 
0% to 20% EtOAc in hexane affording the desired levulinic ester as a colorless oil (260mg, 
0.61 mmol, 36%).
1H NMR (400 MHz, CDCl3) δ 5.86 (d, J = 3.6 Hz, 1H), 4.84 (t, J = 4.1 Hz, 1H), 4.34 (dd, J = 12.4, 
3.1 Hz, 1H), 4.25 (dd, J = 12.4, 4.7 Hz, 1H), 4.03 (d, J = 6.5 Hz, 2H), 4.02 – 3.97 (m, 1H), 3.57 (dd, J 
= 14.5, 10.5 Hz, 1H), 3.14 (dd, J = 14.4, 2.7 Hz, 1H), 2.79 – 2.74 (m, 2H), 2.64 – 2.60 (m, 2H), 2.51 – 
2.42 (m, 1H), 2.19 (s, 3H), 2.11 – 1.98 (m, 1H), 1.52 (s, 3H), 1.35 (s, 3H); 13C{1H} NMR (101 MHz, 
CDCl3) δ 206.4, 172.5, 112.2, 104.9, 79.9, 77.7, 76.2, 63.0, 45.4, 40.9, 37.9, 29.8, 28.3, 27.8, 26.7, 
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26.3, 18.7, 18.6; HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C18H30NaO9S 445.1503; Found 
445.1500. 
(2R,3R,4R,5S)-4-((isobutoxysulfonyl)methyl)-5-(((4-oxopentanoyl)oxy)methyl)tetrahydrofuran-
2,3-diyl diacetate 38: Compound 38 was prepared analogously to the procedure used for the synthesis 
of 16. Purification by flash chromatography on silica gel using a gradient of 0% to 20% EtOAc in 
hexanes gave the desired product 38 as a white solid (250 mg, 0.54 mmol, 89%).
1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 5.32 (d, J = 4.8 Hz, 1H), 4.29 – 4.19 (m, 3H), 4.03 (d, J = 
6.6 Hz, 2H), 3.45 (dd, J = 14.4, 9.8 Hz, 1H), 3.28 (dd, J = 14.4, 4.3 Hz, 1H), 2.92 (tt, J = 9.3, 4.5 Hz, 
1H), 2.80 – 2.75 (m, J = 6.4 Hz, 2H), 2.64 – 2.57 (m, J = 9.7, 3.7 Hz, 2H), 2.19 (s, 3H), 2.14 (s, 3H), 
2.10 (s, 3H), 1.00 (d, J = 1.3 Hz, 3H), 0.98 (d, J = 1.3 Hz, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ 
206.3, 172.4, 169.3, 168.9, 98.3, 81.1, 76.3, 75.9, 65.3, 46.2, 37.8, 37.8, 29.8, 28.3, 27.7, 21.1,  20.6, 
18.6. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – C19H30NaO11S 489.1398; Found 489.1398. 
((2S,3R,4R,5R)-4-acetoxy-3-((isobutoxysulfonyl)methyl)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl 4-oxopentanoate 39: Compound 39 was 
prepared analogously to the procedure used for the synthesis of 17b. Purification by flash 
chromatography on silica gel using a 0% to 80% gradient of EtOAc in hexane gave the desired 
product 39 as a white foam (150 mg, 0.29 mmol, 89%).
1H NMR (500 MHz, CDCl3) δ 8.19 (s, 1H), 7.26 (s, 2H), 7.19 (d, J = 1.2 Hz, 1H), 5.59 (d, J = 2.2 Hz, 
1H), 5.52 (dd, J = 6.8, 2.2 Hz, 1H), 4.43 (t, J = 3.6 Hz, 2H), 4.15 (dt, J = 9.6, 3.4 Hz, 1H), 4.02 (d, J = 
6.6 Hz, 2H), 3.46 (dd, J = 14.4, 9.3 Hz, 1H), 3.25 (dd, J = 14.4, 4.6 Hz, 1H), 3.20 – 3.13 (m, 1H), 2.85 
– 2.77 (m, 2H), 2.61 (td, J = 6.6, 4.8 Hz, 2H), 2.20 (s, 3H), 2.16 (s, 3H), 2.08 – 1.99 (m, 1H), 1.93 (d, 
J = 1.2 Hz, 3H), 0.99 (s, 3H), 0.98 (s, 3H); 13C{1H} NMR (126 MHz, CDCl3) δ 206.6, 172.6, 169.6, 
163.2, 149.6, 137.0, 111.5, 92.5, 80.6, 76.4, 76.1, 62.9, 46.2, 38.0, 37.3, 29.7, 28.3, 27.8, 20.7, 18.6, 
12.4.  HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for - C22H32N2NaO11S 555.1619; Found 555.1629. 
((2S,3R,4R,5R)-4-acetoxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
(((perfluorophenoxy)sulfonyl)methyl)tetrahydrofuran-2-yl)methyl 4-oxopentanoate 40: 
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Compound 40 was prepared analogously to the procedure used for the synthesis of 20b and gave the 
desired PFP ester 40 as a white foam (180 mg,0.28 mmol, 88%).
1H NMR (500 MHz, CDCl3) δ 8.49 (s, 1H), 7.21 (d, J = 1.2 Hz, 1H), 5.62 – 5.57 (m, 2H), 4.51 (dd, J 
= 12.6, 4.1 Hz, 1H), 4.41 (dd, J = 12.6, 3.0 Hz, 1H), 4.17 (dt, J = 9.9, 3.5 Hz, 1H), 3.86 (dd, J = 14.5, 
10.1 Hz, 1H), 3.71 (dd, J = 14.4, 4.0 Hz, 1H), 3.44 – 3.32 (m, 1H), 2.90 – 2.72 (m, 2H), 2.68 – 2.51 
(m, 2H), 2.17 (s, 3H), 2.16 (s, 3H), 1.92 (d, J = 1.1 Hz, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 
206.7, 172.7, 169.5, 163.1, 149.6, 137.2, 111.7, 93.1, 80.5, 76.3, 62.5, 48.5, 38.0, 37.5, 29.6, 27.8, 
20.5, 12.3. 19F NMR (376 MHz, CDCl) δ -150.25 – -151.47 (m), -154.25 – -154.75 (m), -160.16 – -





41: To a solution of 40 (32 mg, 50 µmol) in DMF (2 mL) was added 5’-amino 3’-TBDMS protected 
deoxy-thymidine derivative31 (37 mg, 100 µmol) and DiPEA (18 µL, 100 µmol).  The resulting 
mixture was heated to 60°C by microwave irradiation and stirred for 20 min.  After concentration of 
the reaction mixture in vacuo crude sulfonamide 41 was obtained which was purified by flash 
chromatography on silica gel using a 0% to 5% gradient of MeOH in DCM and the desired 
sulfonamide dinucleotide 41 was obtained as a white foam (34 mg, 37 µmol, 74%).
1H NMR (400 MHz, CDCl3) δ 9.53 (s, 1H), 9.41 (s, 1H), 7.18 – 7.12 (m, 1H), 7.07 (d, J = 1.4 Hz, 
1H), 6.27 (s, 1H), 5.97 (t, J = 7.0 Hz, 1H), 5.57 (dd, J = 6.8, 2.1 Hz, 1H), 5.33 (d, J = 2.1 Hz, 1H), 
4.44 (d, J = 3.8 Hz, 2H), 4.39 (dt, J = 6.6, 3.3 Hz, 1H), 4.15 (dt, J = 8.2, 3.8 Hz, 1H), 3.98 (q, J = 4.6 
Hz, 1H), 3.45 – 3.26 (m, 4H), 3.18 (dd, J = 14.1, 4.0 Hz, 1H), 2.81 – 2.75 (m, 2H), 2.62 – 2.56 (m, 
2H), 2.18 (s, 3H), 2.16 (s, 3H), 1.91 (d, J = 1.2 Hz, 3H), 1.90 (d, J = 1.2 Hz, 3H), 0.89 (s, 9H), 0.09 (s, 
3H), 0.09 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 207.2, 172.8, 170.3, 163.8, 163.5, 150.8, 150.4, 
138.3, 137.6, 111.6, 111.4, 95.3, 86.1, 81.4, 72.8, 63.9, 48.0, 44.7, 39.2, 37.9, 37.6, 29.8, 27.8, 25.7, 
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20.8, 17.9, 12.4, 12.3, -4.7, -4.8. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – C34H51N5NaO14SSi 
836.2819; Found 836.2815. 
 (2R,3R,4R,5S)-4-((N-(((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl)sulfamoyl)methyl)-5-(hydroxymethyl)-
2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl acetate 42: To a 
stirring solution of 41 (430 mg 0.53 mmol) in pyridine was added a 1 M solution of hydrazine hydrate 
in a 3:2 mixture of pyridine and acetic acid (5.3 mL).  The reaction mixture was stirred for 10 min 
followed by concentration in vacuo.  The residue was then redissolved in DCM and this solution was 
washed with 1 M HCl, a saturated NaHCO3 solution and water. After drying over MgSO4, filtration 
and concentration in vacuo crude 42 was obtained, which was purified by flash chromatography on 
silica gel using 0% to 10% MeOH gradient in DCM affording the desired compound as a white solid 
(300 mg, 0.42 mmol, 79%).
1H NMR (400 MHz, CDCl3) δ 9.95 (s, 0H), 10.05 – 9.79 (m, 1H), 7.29 (s, 1H), 7.12 (d, J = 1.5 Hz, 
1H), 6.63 (s, 1H), 6.04 (t, J = 6.9 Hz, 1H), 5.66 – 5.58 (m, 1H), 5.35 (s, 1H), 4.37 (dt, J = 7.1, 3.9 Hz, 
1H), 4.08 – 3.98 (m, 2H), 3.96 (dd, J = 6.5, 3.3 Hz, 1H), 3.85 (d, J = 12.7 Hz, 1H), 3.47 – 3.28 (m, 
5H), 3.10 (d, J = 11.4 Hz, 1H), 2.51 – 2.37 (m, 1H), 2.24 – 2.15 (m, 1H), 2.16 (s, 3H), 1.85 (d, J = 1.0 
Hz, 3H), 1.80 (s, 3H), 0.88 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 
170.3, 164.2, 163.9, 151.0, 150.6, 138.5, 137.5, 111.5, 110.9, 85.8, 84.2, 77.8, 72.4, 60.8, 53.4, 47.5, 
44.3, 39.3, 35.9, 25.7, 20.8, 17.9, 12.3, 12.2, -4.7, -4.8. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – 




yl)tetrahydrofuran-3-yl acetate 43: A solution of 42 (300 mg 0.41 mmol) in pyridine (3 mL), to 
which DMTrCl (170mg 0.50 mmol) was added, was stirred for 4h.  After removal of the solvent in 
vacuo the crude compound 43 was purified by flash chromatography on silica gel using a gradient of 
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0% to 80% EtOAc in hexanes containing 0.1% TEA and gave the desired product as a yellowish solid 
(310mg, 0.30mmol, 72%). 
1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H), 7.47 – 7.39 (m, 2H), 7.35 – 7.17 (m, 8H), 7.01 (d, J = 1.4 
Hz, 1H), 6.83 (d, J = 1.3 Hz, 2H), 6.81 (d, J = 1.3 Hz, 2H), 5.93 (s, 1H), 5.83 (t, J = 7.1 Hz, 1H), 5.70 
– 5.64 (m, 1H), 5.55 (d, J = 2.4 Hz, 1H), 4.34 (dt, J = 6.4, 3.1 Hz, 1H), 4.10 (t, J = 4.3 Hz, 1H), 3.93 
(dt, J = 6.9, 3.7 Hz, 1H), 3.77 (s, 5H), 3.46 (qd, J = 10.8, 3.7 Hz, 2H), 3.41 – 3.31 (m, 2H), 3.23 (q, J 
= 5.9 Hz, 2H), 3.07 (d, J = 10.0 Hz, 1H), 2.60 – 2.48 (m, 1H), 2.15 (s, 3H), 2.14 – 2.09 (m, 1H), 1.85 
(d, J = 1.1 Hz, 3H), 1.64 (d, J = 1.1 Hz, 3H), 0.88 (s, 9H), 0.08 (s, 6H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 169.9, 163.6, 163.4, 158.7, 158.6, 150.5, 150.3, 144.3, 138.1, 137.2, 135.3, 130.2, 130.1, 
128.2, 128.0, 127.1, 113.3, 111.6, 111.4, 87.0, 85.9, 82.2, 72.8, 63.7, 55.2, 53.4, 48.3, 44.4, 39.0, 38.0, 
25.8, 20.8, 17.9, 12.3, 12.1, -4.7, -4.8. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – 




yl)tetrahydrofuran-3-yl acetate 44: A solution of 43 (310 mg 0.30 mmol) in THF (10 mL), to which 
1M TBAF in THF (450 µL 0.46 mmol) was added, was stirred for 1h.  After removal of the solvent in 
vacuo the crude compound 44 was purified by flash chromatography on silica gel using a gradient of 
0% to 80% EtOAc in hexanes containing 0.1% TEA and gave the desired product as a yellowish solid 
(260mg, 0.29mmol, 96%).
1H NMR (400 MHz, CDCl3) δ 7.44 – 7.38 (m, 2H), 7.36 – 7.22 (m, 9H), 7.21 – 7.14 (m, 1H), 6.80 
(dd, J = 9.0, 2.8 Hz, 4H), 6.11 (t, J = 6.8 Hz, 1H), 5.78 – 5.70 (m, 1H), 5.42 (s, 1H), 4.45 (s, 1H), 4.05 
(d, J = 6.9 Hz, 1H), 3.92 (d, J = 4.6 Hz, 1H), 3.76 (d, J = 2.8 Hz, 0H), 3.73 (d, J = 0.9 Hz, 6H), 3.50 – 
3.32 (m, 3H), 3.20 (d, J = 5.6 Hz, 2H), 3.02 (d, J = 10.7 Hz, 1H), 2.85 (q, J = 7.3 Hz, 2H), 2.14 (s, 
3H), 1.84 (s, 3H), 1.67 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 169.9, 
163.6, 163.4, 158.7, 158.7, 150.5, 150.3, 144.3, 138.1, 137.2, 135.3, 130.2, 130.1, 128.2, 128.0, 127.1, 
113.3, 111.6, 111.4, 87.0, 85.9, 82.2, 72.8, 63.7, 55.2, 53.0, 48.3, 44.4, 39.0, 38.1, 25.7, 20.8, 17.9, 
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dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl acetate 45: To a stirred solution of 44 (260 mg, 
0.29 mmol) in dry DCM (5 mL) was added 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite 
(260 mg 0.37 mmol) and DiPEA (130 µL 0.75 mmol) After stirring for 3 h, the solvent was removed 
in vacuo and the crude compound 45 was purified by flash chromatography on silica gel using a 
gradient of  0% to 10% MeOH in DCM containing 0.1% TEA and the desired amidite was obtained as 
a white solid (180 mg, 0.16 mmol, 55%).
31P NMR (162 MHz, CDCl3) δ 149.58 (s), 148.33 (s). HRMS (ESI-TOF) m/z: [M+Na]+ Calcd. for – 
C53H66N7NaO15PS 1126.3931; Found 1126.3967. 
Synthesis and purification of sulfonamide containing antisense oligodeoxynucleotide (DNA-SaASO 
33)
DNA-SaRNA 46 was synthesized using standard solid phase oligonucleotide synthesis protocols on 
an ABI 394 synthesizer.  Phosphoramidites and CPG supports loaded with standard nucleosides were 
purchased from LINK Technologies Ltd (Bellshill, UK).  For the modified phosphoramidite 45 four 
coupling cycles with 10 minutes coupling time each were used.  DNA-SaRNA 46 was cleaved from 
the CPG support overnight by shaking with 1.5 mL of ammonia at 60 °C.  The CPG was washed with 
water and the combined liquid fractions were freeze-dried. DNA-SaRNA  46 was dissolved in water 
and filtered before purification by reverse-phase HPLC on a Dionex UltiMate 3000 System.  The 
purified DNA-SaRNA  33 was freeze dried and the DMT protection group was removed by shaking 
with 1 ml of 80% AcOH for an hour.  After desalting and freeze-drying, pure DNA-SaRNA  46 was 
obtained as a white solid (198 nmol, 19.8%).
Analytical Data of  46
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MALDI-ToF mass spectra were recorded using a Shimadzu Biotech Axima CFR spectrometer, using 
3-hydroxypicolinic acid (HPA) as the matrix.  All mass spectra were recorded in negative mode (Fig 
S1-4). Analytical RP-HPLC was performed on a Dionex UltiMate 3000 system using a Clarity 5 µM 
Oligo-RP column (250 x 4.6 mm) in a triethylammonium acetate (TEAA) Buffer system.  (Buffer A: 
100 mM TEAA pH 7.5 in water. Buffer B 100 mM TEAA pH 7.5 in 80% MeCN. Flow rate: 1 
mL/min)
DNA-SaASO 46: MS: [M-H]- calcd. 3962.7 found 3963.3.  HPLC: retention time 12.0 min
Determination of melting curves by thermal UV-Vis measurements
Complementary oligonucleotides were diluted to 3 µM each in 10 mM Cacodylate buffer (10 mM 
sodium cacodylate, 10 mM KCl, 10 mM MgCl2, 5 mM CaCl2) previously set to the desired pH.  UV 
measurements were obtained using a Shimadzu UV-1800 with an 8-series micro multi cell, each cell 
containing a sample volume of 100 µL.  The UV spectra were obtained over a range from 20 to 90 °C 
for ODN1 using a ramp speed of 1 °C per minute and measurement intervals of 0.4 °C.  The measured 
wavelength was 260 nm. All measurements were performed 3 times to obtain an average value.
Supporting information
1H, 13C, 19F and 31P NMR spectra as well as HPLC and LC-MS traces
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